Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical and molecular background associated with obinutuzumab response in follicular lymphoma
jRCT1060200019Active, not recruiting
- Sponsor
- Okayama University Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of obinutuzumab in follicular lymphoma (FL), sponsored by Okayama University Hospital. Primary endpoint: POD24 rate. Started Jan 2021; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT1060200019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1060200019.